Breast Cancer | Specialty

Extending Adjuvant Chemotherapy Offers No Additional Benefit in Low-Risk Primary Breast Cancer

October 29th 2012

Six cycles of doxorubicin and cyclophosphamide or single-agent paclitaxel do not lead to a superior outcome versus four cycles as adjuvant chemotherapy in women with resected primary breast cancer.

Osteoclast Inhibitors May Prevent Recurrences in Early-Stage Disease

October 26th 2012

An overview of studies looking at the potential of osteoclast inhibitors in the prevention of breast cancer recurrences in the adjuvant setting.

Management of Comorbidities in Early Breast Cancer

October 25th 2012

Novel Strategies for Treatment of Early Breast Cancer, Part II

October 25th 2012

Novel Strategies for Treatment of Early Breast Cancer, Part I

October 25th 2012

Anthracyclines for Early-Stage HER2-Positive Breast Cancer

October 25th 2012

Hormonal and HER2-Targeted Therapy in Early Breast Cancer

October 25th 2012

Dr. Aithal on the HERceptin Adjuvant (HERA) Trial

October 25th 2012

Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.

Dr. Cristofanilli Discusses ALK Amplification in IBC

October 23rd 2012

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.

Dr. Munster on Vorinostat Plus Tamoxifen for Breast Cancer

October 23rd 2012

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

Conference Offers "Deep Dive" Into Managing Clinical Issues

October 22nd 2012

A thorough examination of emerging strategies for the treatment of breast cancer, as well as the clinical data underlying new and existing options, will form the cornerstone of the 9th Annual School of Breast Oncology.

Researchers Remain in Pursuit of Angiogenesis Inhibition

October 19th 2012

Many researchers and oncologists anticipate a role for antiangiogenic strategies in future treatment paradigms; yet just what that role will be remains elusive.

Putting the Genome to Work in Breast Cancer

October 18th 2012

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

Dr. Gralow Explains the Side Effects of Zoledronic Acid

October 17th 2012

Julie R. Gralow, MD, from Seattle Cancer Care Alliance, discusses the side effects associated with the administration of zoledronic acid.

Pink Overload

October 16th 2012

Does "think pink" actually raise awareness of breast cancer?

Dr. Tripathy on the Updated EMILIA T-DM1 Trial Results

October 15th 2012

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the phase III EMILIA trial that examined the T-DM1 for women with HER2-positive breast cancer.

Noted Researcher Offers Overview of Emerging Therapies

October 15th 2012

Within the past two years, the oncology community has seen the FDA approve three practice-changing therapies for breast cancer and the progress of a promising fourth agent, T-DM1.

Beth DuPree, MD, Updates Navigators on Breast Cancer Treatments

October 8th 2012

Updates on breast cancer risk factors, screening methods, and treatments for the nurse navigators who are guiding patients from diagnosis to treatment and, hopefully, through survivorship.

Breast Oncologists Incorporate New Treatments, Grapple With Ongoing Challenges

October 5th 2012

During the 11th International Congress on The Future of Breast Cancer, Hope Rugo, MD, offered a snapshot of the research community's progress in the study and treatment of the disease.

Everolimus Plus Tamoxifen Delivers Benefits in Hormone-Resistant mBC

October 4th 2012

Combining tamoxifen with everolimus increased the clinical benefit rate, time to progression, and overall survival versus tamoxifen alone in postmenopausal women with metastatic breast cancer.